Furthermore, Germline variants of MMR and other DDR genes might be of guiding significance for treatment selection, as MMR deficiency was correlated with immunotherapy response of PD-L1/PD-1 blockade and ATM, ERCC2, or other DDR gene alterations were associated with chemotherapy response (34–36). This evidence concerns the gene CD274 and mismatch repair cancer syndrome 1.